 Adam Green
Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 16 | 2024 | 296 | 6.080 |
Why?
| | Brain Neoplasms | 18 | 2024 | 987 | 4.240 |
Why?
| | Central Nervous System Neoplasms | 8 | 2023 | 126 | 4.050 |
Why?
| | Neoplasms | 9 | 2023 | 2106 | 1.930 |
Why?
| | Ependymoma | 4 | 2023 | 157 | 1.740 |
Why?
| | Glioblastoma | 4 | 2021 | 253 | 1.280 |
Why?
| | Karyopherins | 2 | 2019 | 15 | 1.160 |
Why?
| | Insurance Coverage | 2 | 2019 | 202 | 1.060 |
Why?
| | Child | 28 | 2024 | 18366 | 1.050 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 193 | 1.030 |
Why?
| | Brain Stem Neoplasms | 2 | 2017 | 86 | 1.020 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2021 | 179 | 1.000 |
Why?
| | Healthcare Disparities | 2 | 2021 | 480 | 0.990 |
Why?
| | Cerebellar Neoplasms | 2 | 2023 | 131 | 0.910 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 1897 | 0.900 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 131 | 0.830 |
Why?
| | Radiation | 2 | 2021 | 24 | 0.820 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.790 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 65 | 0.770 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 31 | 0.750 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2021 | 12 | 0.740 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 62 | 0.740 |
Why?
| | Medical Oncology | 2 | 2020 | 228 | 0.720 |
Why?
| | Bone Neoplasms | 1 | 2022 | 194 | 0.700 |
Why?
| | Rhabdomyosarcoma | 1 | 2021 | 55 | 0.700 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 276 | 0.690 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 88 | 0.680 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 15 | 0.680 |
Why?
| | Hydrazines | 2 | 2021 | 28 | 0.680 |
Why?
| | Infant | 12 | 2023 | 7937 | 0.660 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 265 | 0.660 |
Why?
| | Retinoblastoma | 2 | 2016 | 26 | 0.650 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 12 | 0.650 |
Why?
| | Optic Chiasm | 1 | 2019 | 18 | 0.650 |
Why?
| | Triazoles | 2 | 2021 | 130 | 0.620 |
Why?
| | Humans | 45 | 2024 | 114937 | 0.620 |
Why?
| | Craniopharyngioma | 1 | 2019 | 65 | 0.610 |
Why?
| | Combined Modality Therapy | 6 | 2021 | 1126 | 0.610 |
Why?
| | Adolescent | 15 | 2023 | 17829 | 0.600 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 934 | 0.600 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2017 | 8 | 0.600 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 11 | 0.590 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 863 | 0.590 |
Why?
| | Everolimus | 1 | 2017 | 61 | 0.590 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 157 | 0.590 |
Why?
| | Socioeconomic Factors | 5 | 2022 | 1081 | 0.580 |
Why?
| | Morpholines | 1 | 2017 | 102 | 0.570 |
Why?
| | Neuroimaging | 1 | 2019 | 248 | 0.560 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1054 | 0.550 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 56 | 0.550 |
Why?
| | Prognosis | 7 | 2022 | 3344 | 0.540 |
Why?
| | Retinal Neoplasms | 1 | 2016 | 21 | 0.530 |
Why?
| | Carcinoma | 1 | 2017 | 199 | 0.520 |
Why?
| | Child, Preschool | 11 | 2023 | 9086 | 0.520 |
Why?
| | NF-kappa B | 1 | 2019 | 637 | 0.510 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 400 | 0.510 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1361 | 0.490 |
Why?
| | Neutropenia | 1 | 2015 | 125 | 0.480 |
Why?
| | Genetic Variation | 1 | 2019 | 876 | 0.480 |
Why?
| | Oxadiazoles | 1 | 2014 | 32 | 0.480 |
Why?
| | Neoplasm Grading | 3 | 2021 | 243 | 0.480 |
Why?
| | Acrylamides | 1 | 2014 | 42 | 0.470 |
Why?
| | Virilism | 1 | 2014 | 5 | 0.470 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2014 | 110 | 0.470 |
Why?
| | Thiazoles | 1 | 2014 | 110 | 0.460 |
Why?
| | Fever | 1 | 2015 | 279 | 0.460 |
Why?
| | Fathers | 1 | 2014 | 45 | 0.450 |
Why?
| | SEER Program | 3 | 2020 | 196 | 0.450 |
Why?
| | Delayed Diagnosis | 1 | 2014 | 71 | 0.450 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2014 | 48 | 0.440 |
Why?
| | Adrenocortical Carcinoma | 1 | 2014 | 47 | 0.440 |
Why?
| | Rare Diseases | 1 | 2014 | 89 | 0.440 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 193 | 0.440 |
Why?
| | Young Adult | 9 | 2023 | 10478 | 0.400 |
Why?
| | DNA Copy Number Variations | 2 | 2023 | 159 | 0.390 |
Why?
| | Testosterone | 1 | 2014 | 343 | 0.360 |
Why?
| | Infant, Newborn | 6 | 2020 | 5035 | 0.350 |
Why?
| | Female | 18 | 2023 | 59581 | 0.340 |
Why?
| | Social Class | 3 | 2023 | 204 | 0.340 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2023 | 1148 | 0.330 |
Why?
| | Male | 17 | 2023 | 55663 | 0.330 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 180 | 0.330 |
Why?
| | Quality Improvement | 1 | 2015 | 954 | 0.300 |
Why?
| | United States | 7 | 2023 | 12211 | 0.290 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1523 | 0.280 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 399 | 0.280 |
Why?
| | Proto-Oncogene Proteins | 2 | 2020 | 611 | 0.270 |
Why?
| | Survival Analysis | 2 | 2020 | 1220 | 0.270 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1477 | 0.270 |
Why?
| | Autophagy | 2 | 2019 | 234 | 0.260 |
Why?
| | Cohort Studies | 4 | 2023 | 4903 | 0.260 |
Why?
| | Histones | 2 | 2021 | 536 | 0.260 |
Why?
| | Prospective Studies | 3 | 2023 | 6218 | 0.250 |
Why?
| | Cell Line, Tumor | 5 | 2020 | 2725 | 0.240 |
Why?
| | Retrospective Studies | 5 | 2023 | 12544 | 0.240 |
Why?
| | DNA Methylation | 3 | 2023 | 496 | 0.220 |
Why?
| | Case-Control Studies | 2 | 2023 | 3008 | 0.220 |
Why?
| | Astrocytoma | 1 | 2023 | 109 | 0.210 |
Why?
| | Teratoma | 1 | 2023 | 92 | 0.210 |
Why?
| | Rhabdoid Tumor | 1 | 2023 | 80 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1856 | 0.200 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 90 | 0.200 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 14 | 0.200 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 523 | 0.200 |
Why?
| | Medulloblastoma | 1 | 2023 | 172 | 0.190 |
Why?
| | Gene Ontology | 1 | 2021 | 45 | 0.190 |
Why?
| | Cause of Death | 1 | 2023 | 363 | 0.190 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 58 | 0.190 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 136 | 0.190 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 40 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2021 | 9105 | 0.190 |
Why?
| | Gene Amplification | 1 | 2021 | 97 | 0.190 |
Why?
| | Infusions, Intra-Arterial | 1 | 2021 | 46 | 0.190 |
Why?
| | Leukocytes | 1 | 2022 | 277 | 0.180 |
Why?
| | Geography | 1 | 2021 | 181 | 0.180 |
Why?
| | Benzamides | 2 | 2019 | 169 | 0.180 |
Why?
| | Cell Survival | 3 | 2019 | 1022 | 0.180 |
Why?
| | Recurrence | 1 | 2023 | 937 | 0.180 |
Why?
| | Cyclophosphamide | 1 | 2021 | 217 | 0.180 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 32 | 0.170 |
Why?
| | Immunophenotyping | 1 | 2021 | 277 | 0.170 |
Why?
| | Anemia, Sickle Cell | 1 | 2023 | 216 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 258 | 0.170 |
Why?
| | Pedigree | 1 | 2021 | 467 | 0.170 |
Why?
| | Protein Domains | 1 | 2021 | 207 | 0.170 |
Why?
| | Sirolimus | 1 | 2021 | 181 | 0.170 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.170 |
Why?
| | Eye Enucleation | 2 | 2016 | 12 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 434 | 0.170 |
Why?
| | Age Distribution | 1 | 2020 | 340 | 0.160 |
Why?
| | Sex Distribution | 1 | 2020 | 336 | 0.160 |
Why?
| | Cell Differentiation | 2 | 2017 | 1699 | 0.160 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 273 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2326 | 0.160 |
Why?
| | Influenza Vaccines | 1 | 2023 | 497 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3053 | 0.160 |
Why?
| | Pyrimidines | 2 | 2019 | 378 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 369 | 0.150 |
Why?
| | Genes, p53 | 1 | 2017 | 62 | 0.150 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 55 | 0.150 |
Why?
| | Transfection | 1 | 2019 | 870 | 0.140 |
Why?
| | Mortality | 1 | 2019 | 288 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 880 | 0.140 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 96 | 0.140 |
Why?
| | Immunotherapy | 1 | 2021 | 475 | 0.140 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 441 | 0.140 |
Why?
| | Disease Progression | 1 | 2023 | 2392 | 0.130 |
Why?
| | Radiotherapy | 1 | 2017 | 176 | 0.130 |
Why?
| | Phenotype | 1 | 2024 | 2817 | 0.130 |
Why?
| | Transcriptome | 1 | 2021 | 728 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 344 | 0.130 |
Why?
| | Cell Cycle | 1 | 2017 | 544 | 0.120 |
Why?
| | Macaca fascicularis | 1 | 2014 | 51 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1019 | 0.120 |
Why?
| | Indoles | 1 | 2017 | 306 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 536 | 0.120 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 85 | 0.120 |
Why?
| | Mutism | 1 | 2014 | 4 | 0.120 |
Why?
| | Adrenalectomy | 1 | 2014 | 60 | 0.120 |
Why?
| | Insurance, Health | 1 | 2016 | 244 | 0.120 |
Why?
| | Administration, Cutaneous | 1 | 2014 | 117 | 0.110 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 190 | 0.110 |
Why?
| | Infratentorial Neoplasms | 1 | 2014 | 46 | 0.110 |
Why?
| | Phosphorylation | 1 | 2017 | 1572 | 0.110 |
Why?
| | Sulfonamides | 1 | 2017 | 445 | 0.110 |
Why?
| | Risk Factors | 2 | 2017 | 8637 | 0.110 |
Why?
| | Diagnostic Errors | 1 | 2014 | 151 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 642 | 0.100 |
Why?
| | Hydrocortisone | 1 | 2014 | 270 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 706 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 347 | 0.100 |
Why?
| | Dexamethasone | 1 | 2014 | 317 | 0.100 |
Why?
| | Epigenomics | 2 | 2023 | 102 | 0.090 |
Why?
| | Weight Gain | 1 | 2014 | 451 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4427 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2211 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 678 | 0.080 |
Why?
| | Animals | 3 | 2023 | 31839 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2015 | 802 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2382 | 0.070 |
Why?
| | Mutation | 3 | 2023 | 3354 | 0.070 |
Why?
| | Brain | 3 | 2023 | 2372 | 0.070 |
Why?
| | Apoptosis | 1 | 2014 | 2371 | 0.060 |
Why?
| | Time Factors | 1 | 2015 | 6125 | 0.060 |
Why?
| | Adult | 3 | 2021 | 30608 | 0.060 |
Why?
| | Mice | 2 | 2023 | 14936 | 0.060 |
Why?
| | Histology | 1 | 2023 | 3 | 0.060 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 18 | 0.060 |
Why?
| | Microbubbles | 1 | 2023 | 40 | 0.060 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 67 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2023 | 106 | 0.050 |
Why?
| | Mitosis | 1 | 2023 | 164 | 0.050 |
Why?
| | Registries | 2 | 2023 | 1760 | 0.050 |
Why?
| | Cerebellum | 1 | 2023 | 200 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2021 | 38 | 0.050 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 35 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2021 | 96 | 0.050 |
Why?
| | Immunization | 1 | 2023 | 402 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 390 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2023 | 296 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2021 | 138 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2023 | 436 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 460 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 352 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 731 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2021 | 282 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 817 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 81 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 344 | 0.040 |
Why?
| | Blotting, Western | 1 | 2019 | 1151 | 0.030 |
Why?
| | Chromatin | 1 | 2020 | 428 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 316 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1087 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 796 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1317 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1205 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1530 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1183 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2015 | 201 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 4635 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1644 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 26806 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2199 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 4525 | 0.020 |
Why?
| | Aged | 1 | 2021 | 19122 | 0.010 |
Why?
|
|
Green's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|